annb0t
Top 20
Melbourne, Victoria --News Direct-- Incannex Healthcare Ltd
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical trial investigating the companyâs IHL-42X for the treatment of Obstructive Sleep Apnoea (OSA). This Phase 2/3 clinical trial will assess the safety and efficacy of IHL-42X in people with OSA who are intolerant, non-compliant or naï...
>>> Read more: Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical trial investigating the companyâs IHL-42X for the treatment of Obstructive Sleep Apnoea (OSA). This Phase 2/3 clinical trial will assess the safety and efficacy of IHL-42X in people with OSA who are intolerant, non-compliant or naï...
>>> Read more: Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial
